These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 28687355)

  • 41. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.
    Kaisaki PJ; Cutts A; Popitsch N; Camps C; Pentony MM; Wilson G; Page S; Kaur K; Vavoulis D; Henderson S; Gupta A; Middleton MR; Karydis I; Talbot DC; Schuh A; Taylor JC
    PLoS One; 2016; 11(9):e0162809. PubMed ID: 27626278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
    Kahana-Edwin S; McCowage G; Cain L; Saletta F; Yuksel A; Graf N; Karpelowsky J
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28594. PubMed ID: 32881242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A liquid biopsy for head and neck cancers.
    Schmidt H; Kulasinghe A; Perry C; Nelson C; Punyadeera C
    Expert Rev Mol Diagn; 2016; 16(2):165-72. PubMed ID: 26631411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating tumor DNA as a liquid biopsy for cancer.
    Heitzer E; Ulz P; Geigl JB
    Clin Chem; 2015 Jan; 61(1):112-23. PubMed ID: 25388429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.
    Openshaw MR; Page K; Fernandez-Garcia D; Guttery D; Shaw JA
    Expert Rev Mol Diagn; 2016 Jul; 16(7):751-5. PubMed ID: 27144417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cell-free DNA as a post-treatment surveillance strategy: current status.
    Burgener JM; Rostami A; De Carvalho DD; Bratman SV
    Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
    Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
    J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liquid biopsy of circulating tumor DNA and biosensor applications.
    Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
    Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
    Newman AM; Bratman SV; To J; Wynne JF; Eclov NC; Modlin LA; Liu CL; Neal JW; Wakelee HA; Merritt RE; Shrager JB; Loo BW; Alizadeh AA; Diehn M
    Nat Med; 2014 May; 20(5):548-54. PubMed ID: 24705333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient monitoring through liquid biopsies using circulating tumor DNA.
    Ulz P; Heitzer E; Geigl JB; Speicher MR
    Int J Cancer; 2017 Sep; 141(5):887-896. PubMed ID: 28470712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample.
    Rothwell DG; Smith N; Morris D; Leong HS; Li Y; Hollebecque A; Ayub M; Carter L; Antonello J; Franklin L; Miller C; Blackhall F; Dive C; Brady G
    Mol Oncol; 2016 Apr; 10(4):566-74. PubMed ID: 26639657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
    Cabel L; Proudhon C; Mariani P; Tzanis D; Beinse G; Bieche I; Pierga JY; Bidard FC
    Eur J Surg Oncol; 2017 May; 43(5):949-962. PubMed ID: 28185687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
    Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
    PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.